Drug intelligence / Profile preview

ICM-502

Development stage: Preclinical
Lead developer: ICM
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intraarticular

Overview

ICM-502 is an adeno-associated virus (AAV)-based gene therapy being developed by ICM Co., Ltd. for the treatment of osteoarthritis in canines. It is a veterinary adaptation of the company's lead human candidate, ICM-203. The therapy is designed to deliver specific therapeutic genes directly into the joint space via intra-articular injection, aiming to provide localized treatment and minimize systemic exposure. While the specific molecular target has not been publicly disclosed, the therapy leverages AAV vector technology to modulate the joint environment and address the underlying pathology of canine osteoarthritis.

Other names: ICM-502-ICM-AAV gene therapy-Osteoarthritis (Canine)

Beyond the preview

Go deeper on ICM-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICM-502.

Explore the full profile